Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The Pracasil Plus base enhances bioavailability while reducing irritation and occlusion-induced maceration
Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J
Probably because the studies, although promising, were not considered to have any major therapeutic benefit
Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
The key is to match the tool to the task
US$ 27.22
US$ 28.46
US$ 26.36
US$ 28.42
